T cells, particularly activated CD4⁺ cells, maintain anti-CD20-mediated NK cell viability and antibody dependent cellular cytotoxicity.

ABSTRACT: Anti-CD20 monoclonal antibody (mAb) therapy is a mainstay of therapy for B cell malignancies, however many patients fail to respond or eventually develop resistance. The current understanding of mechanisms responsible for this resistance is limited. When peripheral blood mononuclear cells of healthy donors were cultured with Raji cells for 7 days, rituximab (RTX) induced NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC), enhanced NK cell viability and increased or maintained NK expression of CD56, CD16, CD57 and KIR. T cells, mainly CD4⁺, mediated these changes in a contact-dependent manner, with local T cell production of IL2 playing a central role. Similar findings were found when autologous B cells were used as target cells demonstrating the need for T cell hel

SUBMITTER: Wang Z 

PROVIDER: S-EPMC8783893 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature